WFU
顯示具有 Alzheimer's disease 標籤的文章。 顯示所有文章
顯示具有 Alzheimer's disease 標籤的文章。 顯示所有文章

2024年1月31日 星期三

Clinical Evidence of HIGH BIOAVAILABILITY THERACURMIN and Regular Curcumin

 

In the previous article, we discussed the effects of Highly Bioavailable Curcumin-Theracurmin on "preventing dementia" and its "protective effects on patients with existing dementia or mild cognitive impairment." 

This time, we will explore the various clinical benefits of Theracurmin.

 

The following are medical papers found using Theracurmin as the keyword in PubMed (a global medical literature search engine). 

Dr. Huang has categorized them based on different types.

 

I. Human Trials Evidence

a. Knee Joint Cartilage Protection

"The Oral Administration of Highly-Bioavailable Curcumin for One Year Has Clinical and Chondro-Protective Effects: A Randomized, Double-Blinded, Placebo-Controlled Prospective Study"

Arthrosc Sports Med Rehabil. 2022 Jan 13;4(2):e393-e402 (IF:1.66)

 

Randomized controlled trial:

43 patients over 20 years old undergoing knee joint surgery due to joint disease.

Experimental group (n=23) received 180mg Theracurmin® daily, and placebo group (n=20) continued for 12 months.

Evaluation included the Japanese Orthopaedic Association Knee Osteoarthritis Score (JOA), Visual Analog Scale (VAS), and Japanese Knee Osteoarthritis Measure (JKOM) as clinical symptoms.

T2 mapping on magnetic resonance imaging was used as an indicator of cartilage protection.

Intraoperative ultrasound evaluation of joint cartilage was performed as a standard for measuring cartilage protection.


Results:

No significant differences were observed between the experimental and placebo groups in JOA, VAS, JKOM values, and T2 mapping.

However, during the second arthroscopic examination, the experimental group showed significantly better cartilage stiffness and surface roughness than the placebo group.


Conclusion:

Compared to the placebo, oral administration of Theracurmin® for one year demonstrated significantly better cartilage protection without worse clinical effects or adverse events.

 

b. Knee Osteoarthritis

"The Efficacy and Safety of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A 6-Month Open-Labeled Prospective Study"

Clin Med Insights Arthritis Musculoskelet Disord. 2020 Aug 12:13:1179544120948471 (IF:2.6)

 

Open-label prospective study:

Selected 50 patients over 40 years old with Kellgren-Lawrence II, III, or IV grade knee osteoarthritis.

Received 180 mg Theracurmin daily for 6 months.

Patients were assessed for knee joint symptoms (JOA, VAS, JKOM) at 0, 1, 2, 3, 4, 5, and 6 months.

Results:

During the study period, 5 participants dropped out, but none due to major issues.

No significant adverse effects were observed with Theracurmin treatment.

Effective group: 34 cases (75.6%), ineffective group: 11 cases.

 

Conclusion:

This study demonstrated the safety and efficacy of Theracurmin® in treating various types of knee osteoarthritis. Theracurmin shows significant potential in treating human knee osteoarthritis.


c. Short-term Effects on Knee Osteoarthritis

"Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study"

J Orthop Sci. 2014 Nov;19(6):933-9 (IF:1.805)

 

Randomized, double-blind, placebo-controlled trial:

50 cases of Kellgren-Lawrence II or III grade knee osteoarthritis patients over 40 years old were included in this prospective clinical study.

Received 180mg Theracurmin® or placebo daily for 8 weeks.

Patients were assessed for knee joint symptoms using JOA, VAS, and JKOM scoring systems at 0, 2, 4, 6, and 8 weeks.

Evaluation included the need for knee joint replacement surgery and NSAIDS usage.

 

Results:

After 8 weeks of treatment, the Theracurmin group showed significantly lower knee pain VAS scores compared to the placebo group.

Theracurmin was more effective in reducing dependence on celecoxib, but no significant adverse effects were observed.

 

Conclusion:

Theracurmin® demonstrates potential in treating human knee osteoarthritis.


 


d. Muscle Damage

"Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin"

Eur J Appl Physiol. 2015 Sep;115(9):1949-57 (IF:3.346)

 

Randomized controlled trial:

14 young men (24 ± 1 years) performed 50 maximal eccentric contractions of the elbow flexors.

Received 150 mg Theracurmin® or placebo 12 hours before and after each exercise.

The Theracurmin group showed smaller decreases in maximum voluntary contraction (MVC) torque and smaller peaks in serum CK activity.

 

Conclusion:

Theracurmin® intake can alleviate muscle damage.

 

e. Crohn's Disease

"Highly Bioavailable Curcumin Derivative Ameliorates Crohn‘s Disease Symptoms: A Randomized, Double-Blind, Multicenter Study"

J Crohns Colitis. 2020 Dec 2;14(12):1693-1701 (IF:8.0)

 

Randomized controlled trial:

Conducted a randomized, double-blind study in five independent medical centers in Japan.

Patients with mild to moderate Crohn's disease took Theracurmin® (360mg/day, n=20) or placebo (n=10) for 12 weeks.

The experimental group showed a significant decrease in clinical disease activity at week 12, a reduction in endoscopic severity, and significant healing of anal lesions.

 

Conclusion:

Theracurmin® exhibits significant clinical and endoscopic efficacy and good safety in patients with mild to moderate Crohn's disease.

(The endoscopic changes before and after administering Theracurmin in two patients with Crohn's disease reveal the healing mucosa.)

 

f. Common Cold

"Effects of Highly Bioavailable Curcumin Supplementation on Common Cold Symptoms and Immune and Inflammatory Functions in Healthy Japanese Subjects: A Randomized Controlled Study"

J Diet Suppl. 2024;21(1):71-98 (IF:0.442)

 

Randomized controlled trial:

A randomized, double-blind, placebo-controlled study was conducted on 99 healthy Japanese adults for 12 weeks.

Participants were divided into three groups: TS-P1 (Theracurmin Super [TS-P1], 150 mg/day), CR-033P (Theracurmin [CR-033P], 150 mg/day), and placebo (each group n=33).

 

Results:

The cumulative days of persistent common cold symptoms were significantly lower in the TS-P1 and CR-033P groups (both Theracurmin groups) compared to the placebo group. No adverse reactions were observed.

 

g. Stabilize Oxidized Low-Density Lipoprotein (AT-LDL)

"Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus"

J Diabetes Res. 2019 Nov 23:2019:8208237 (IF:4.016)

 

Randomized controlled trial:

Patients with Impaired  Glucose Tolerance and Diabetes Mellitus:

Theracurmin® demonstrated no significant difference in HbA1C levels but significantly stabilized α1-antitrypsin-low-density lipoprotein (AT-LDL) levels compared to the placebo group.

 

Mild COPD:

"Highly Absorptive Curcumin Reduces Serum Atherosclerotic Low-Density Lipoprotein Levels in Patients with Mild COPD"

Int J Chron Obstruct Pulmon Dis. 2016 Aug 26:11:2029-34 (IF:3.157)

 

Theracurmin® resulted in a significant lower percent change in AT-LDL levels in patients with mild COPD, suggesting a potential preventive effect on cardiovascular events. 

 

h. Chemobrain Improvement

Title: "The Effect of Theracurmin on Cognitive Function in an Older Patient with Chemobrain"

Clin Interv Aging. 2020 May 19:15:691-693 (IF:3.829)


A case report demonstrated cognitive improvement in a 76-year-old breast cancer patient with chemobrain after three months of Theracurmin® treatment.

 

II. Animal Experiments:

 

a. Fatty Liver:

Title: "Theracurmin Prevents High Fat Diet-Induced Hepatic Steatosis Development in Mice"

Toxicol Res. 2019 Oct;35(4):403-410 (IF:2.68)

 

Theracurmin® significantly reduced triglyceride levels and prevented hepatic fat accumulation induced by a high-fat diet in mice.

 

b. Hearing Loss Prevention:

Title: "Preventive Effect of Curcumin on Hearing Loss Induced by Noise in Mice"

J Pharmacol Sci. 2017 Aug;134(4):225-233 (IF:3.578)

 

Theracurmin® demonstrated a strong preventive effect against hearing loss induced by repeated exposure to noise in mice.

 

c. Parasitic Infection:

Title: "Protective Effects of Theracurmin Treatment during Trypanosoma cruzi Infection in Mice"

Front Cell Infect Microbiol. 2023 Mar 24:13:1143360 (IF:5.7)

 

Theracurmin® showed protective effects on testicular function in mice infected with Trypanosoma cruzi.

 

d. Osteoarthritis:

Title: "Highly Bioavailable Curcumin Suppresses Articular Cartilage Damage in Rats with Osteoarthritis"

Food Sci Biotechnol. 2019 Oct 5;29(2):251-263. (IF:3.231)

 

Theracurmin® significantly improved weight distribution and reduced markers of cartilage damage in rats with osteoarthritis.

 

e. Inflammatory Bowel Disease (IBD):

Title: "Nanoparticle Curcumin Ameliorates Experimental Colitis in Mice"

PLoS One. 2017 Oct 6;12(10):e0185999 (IF: 3.752)

Theracurmin® improved various parameters in mice with colitis, indicating its potential as a treatment for IBD.

 

f. Familial Adenomatous Polyposis (FAP):

Title: "Theracurmin Inhibits Intestinal Polyp Development in Apc-Mutant Mice"

Cancer Sci. 2020 Apr;111(4):1367-1374 (IF: 6.518)

 

Theracurmin® inhibited intestinal polyp development in Apc-mutant mice, suggesting an anti-inflammatory effect.

 

g. Brain Injury:

Title: "Potential Protective Effect of Highly Bioavailable Curcumin on Oxidative Stress in Mice Brain"

Food Funct. 2014 May;5(5):984-9 (IF:6.317)

 

Theracurmin® demonstrated protective effects against oxidative stress-induced brain damage in mice.

 

III. Cellular Experiments:

 

a. Esophageal Squamous Cell Carcinoma:

Title: "Combination Treatment with Highly Bioavailable Curcumin Exhibits Antitumor Effects on Esophageal Squamous Cell Carcinoma"

J Gastroenterol. 2019 Aug;54(8):687-698 (IF: 6.772)

 

Theracurmin demonstrated cytotoxic effects on esophageal squamous cell carcinoma cells and enhanced antitumor activity when combined with an NQO1 inhibitor.

 

b. Esophageal Adenocarcinoma:

Title: "Nano-Curcumin Inhibits Proliferation of Esophageal Adenocarcinoma Cells"

Front Oncol. 2013 May 29:3:137 (IF:5.738)

 

Theracurmin® significantly reduced the proliferation of esophageal adenocarcinoma cells without affecting normal esophageal cells.

 

c. Prostate and Bladder Cancer:

Title: "Theracurmin Efficiently Inhibits the Growth of Human Prostate and Bladder Cancer Cells"

Oncol Rep. 2016 Mar;35(3):1463-72 (IF: 4.2)

 

Theracurmin® induced apoptotic cell death and cell cycle disruption, showing potential as a supplementary anticancer agent.

 

The above are the globally published research results on high bioavailability curcumin, Theracurmin. 

In fact, curcumin has many clinical applications. 

The following list highlights proven effective outcomes of general curcumin from a review study [Curcumin: Biological Activities and Modern Pharmaceutical Forms. Antibiotics (Basel) 2022 Jan 20;11(2):135]:

 

Finally, the paper includes images summarizing the various benefits of curcumin.


2024年1月29日 星期一

A New Opportunity for Dementia Prevention - High Bioavailability Theracurmin!

 

The previous article reviewed traditional methods for preventing and treating dementia and found no ideal preventive measures. 

Does this mean there are no options left? 

Not quite. 

There is a new, evidence-based, and relatively unknown preventive opportunity: high bioavailability curcumin, known as Theracurmin!

 

In fact, traditional forms of curcumin have been studied extensively for their antioxidant, anti-inflammatory, and free-radical scavenging effects. 

In Alzheimer's mouse models, curcumin has been shown to reduce β-amyloid proteins and plaques, with efficacy even at low doses (160 ppm, reducing by 43-50%).

 

A survey study in 2006 investigated the association between daily curry consumption among elderly individuals (n=1,010, aged 60-93) and cognitive function. 

The study found that individuals who consumed curry "occasionally" and "often or very often" scored significantly higher on the Mini-Mental State Examination (MMSE) compared to those who consumed curry "never or rarely." 

While this suggests that curry consumption might improve cognitive abilities, the study's reliance on surveys introduces potential biases and difficulties in quantifying curcumin intake, given that curry contains only 3% curcumin.

Subsequent studies on traditional curcumin revealed varied dosages from 1 to 4 grams per day. 

Unfortunately, these studies failed to demonstrate significant effects, largely due to curcumin's poor aqueous solubility, very low bioavailability, instability at alkaline pH, and rapid metabolism.

 

To overcome these limitations, Japan introduced high bioavailability oral curcumin in 2011, utilizing colloidal nanoparticles. 

In rats, this formulation exhibited over 40 times higher AUC (area under the blood concentration-time curve) compared to traditional curcumin, while in healthy human volunteers, it showed 27 times higher AUC. 

Additionally, it exhibited inhibitory effects on alcohol intoxication and reduced blood acetaldehyde levels. 

Because of its significantly improved bioavailability, researchers believe it can offer clinical benefits at lower doses.

 

Although high bioavailability oral curcumin emerged in 2011, its relevance to dementia-related research wasn't explored until 2018 when Professor Gary Small and his team at the University of California, Los Angeles (UCLA) published findings. 

Their research demonstrated that Theracurmin from Japan had the highest blood concentrations among three different curcumin formulations, making it the most suitable option for their study.

[Comparison of blood absorption kinetics of three curcumins 0.5-6 hours after taking, among which Theracurmin® has the fastest absorption rate (T-max 2hr), the highest peak concentration and area under the curve]
 

Their subsequent 18-month randomized controlled trial involved 40 (selected from 259 volunteers) non-demented elderly individuals (aged 51-84). 

Results showed that participants who took Theracurmin (90mg twice daily) experienced significant improvements in verbal memory, visual memory, and attention compared to the placebo group. 

Furthermore, FDDNP-PET scans (detect Aβ plaques early) indicated stability in Theracurmin group while the placebo group showed increased binding, suggesting that high bioavailability curcumin effectively improves memory and attention in non-demented adults and may prevent Alzheimer's (plaque deposition).


To summarize, this study highlights several key points:

1.                    The first long-term (18 months) double-blind trial of a bioavailable form of curcumin for non-demented adults.

2.                    Daily Theracurmin intake significantly improved memory and attention.

3.                    Changes in FDDNP-PET scans post-treatment correlated with behavioral and cognitive improvements, possibly linked to reduced plaque and tangle accumulation in emotion regulation and memory brain regions.

4.                    The cognitive benefits of curcumin may stem from its anti-inflammatory and/or anti-amyloid brain effects.

 

Given the efficacy demonstrated in non-demented adults, what about research focusing on those already suffering from dementia or Alzheimer's?

 

Indeed, there is! 

In 2021, Dokuz Eylül University in Turkey published a study on Theracurmin in patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD). 

Among diagnosed Alzheimer's patients (n=52), those not taking Theracurmin (control group, n=33) showed declines in MMSE, MOCA, and instrumental ADL scores, while those in the Theracurmin treatment group (n=19) maintained stability. 

In patients with mild cognitive impairment (n=41), the control group (n=24) showed declines in instrumental ADL scores, with three progressing to Alzheimer's. Conversely, the Theracurmin group (n=17) showed stable instrumental ADL scores, with only one progressing to AD. 

Therefore, high bioavailability curcumin not only prevents Alzheimer's but also offers considerable protection for those with Alzheimer's or mild cognitive impairment.

 

In conclusion, Theracurmin's high bioavailability not only improves upon the poor absorption and rapid metabolism of traditional curcumin but also requires minimal dosage to be effective. 

What’s even better is that it has proven effects in preventing dementia, but it does not have the disadvantages of side effects of drugs. 

It can be taken with peace of mind just like ordinary health foods.

 

In addition to its role in preventing dementia, curcumin has various clinically proven benefits, which Dr. Huang will explore in the next article. 

Stay tuned for insights into the clinical benefits of high bioavailability Theracurmin and traditional curcumin!

 

References:

 

Curry Consumption and Cognitive Function in the Elderly

Am J Epidemiol. 2006 Nov 1;164(9):898-906 (IF:5.363)

https://academic.oup.com/aje/article/164/9/898/87190?login=false

 

Recent developments in formulation design for improving oral bioavailability of curcumin: A review

Journal of Drug Delivery Science and Technology Vol 60, Dec 2020 (IF:5.062)

https://www.sciencedirect.com/science/article/abs/pii/S177322472031371X

 

舊型薑黃素研究:

Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease

J Clin Psychopharmacol. 2008 Feb;28(1):110-3 (IF:3.118)

 

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Alzheimers Res Ther 2012;4:43 (IF:8.831)

 

Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults

Br J Nutr. 2016 Jun;115(12):2106-13 (IF:4.125)

 

Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population 

J Psychopharmacol 2015; 29:642–651 (IF:4.1)

 

高生物利用率薑黃素:

Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial

Am J Geriatr Psychiatry. 2018 Mar;26(3):266-277 (IF:7.996)

 

Theracurmin Supplementation May be a Therapeutic Option for Older Patients with Alzheimer’s Disease: A 6-Month Retrospective F/U Study 

Curr Alzheimer Res. 2021;18(14):1087-1092 (IF:3.04)

 

Innovative Preparation of Curcumin for Improved Oral Bioavailability

Biol Pharm Bull 2011;34:660–665 (IF:2.0)